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Transient global cerebral ischemia causes loss of pyramidal cells in CA1 region of hippocampus. In this study, we investigated the
neurotrophic eﬀect of the immunosuppressant agent FK506 in rat after global cerebral ischemia. Both common carotid arteries
were occluded for 20 minutes followed by reperfusion. In experimental group 1, FK506 (6mg/kg) was given as a single dose
exactly at the time of reperfusion. In the second group, FK506 was administered at the beginning of reperfusion, followed by
its administration intraperitoneally (IP) 6, 24, 48, and 72 hours after reperfusion. FK506 failed to show neurotrophic eﬀects on
CA1 region when applied as a single dose of 6mg/kg. The cell number and size of the CA1 pyramidal cells were increased, also
the number of cell death decreased in this region when FK506 was administrated 48h after reperfusion. This work supports the
possible use of FK506 in treatment of ischemic brain damage.
1.Introduction
Reperfusion injury plays an important role in the brain
ischemia cascade, which is involved in stroke and brain
trauma. It is due to the inﬂammatory response of injured
tissues [1]. Returned blood ﬂow can reintroduce oxygen
which can damage proteins, DNA, and plasma membranes
of the cells. Plasma membrane damage may in turn induce
the release of more free radicals. These processes may play
an important role in redox signaling indirectly and cause cell
apoptosis [2].
Certain areas of the brain and certain types of neurons
which are more sensitive to cerebral ischemia are pyramidal
neurons of the CA1 region of the hippocampus [3, 4].
Apoptosis is the most important process in CA1 neurons
exposed to transient global ischemia. Apoptotic cell death
of neurons can be limited by inhibition of macromolecular
synthesis and of caspase activity [5]. Therefore, the attempts
have predominantly been concentrated on prevention of
acute cell death to help stroke patients. More than one
hundred agents have proven to be neuroprotective in experi-
mental models [6].
Unlike the promising results from animal models in
preventing these types of cell death, unfortunately, no ef-
fective pharmacologic strategy has been found to deal with
the problem of ischemia. This may be due to lack of eﬃcacy
a n dp r e s e n c eo fu n w a n t e ds i d ee ﬀects [7, 8].
Recently, using immunophilin ligands has been consid-
ered as a potential and appropriate strategy for neuroprotec-
tion. Since it was observed that tacrolimus (FK506), a useful
immunosuppressant used in organ transplantation, provides2 Stroke Research and Treatment
neuroprotection against glutamate-induced neurotoxicity
in vitro and prevents hippocampal neuronal damage in
a model of transient global ischemia, the importance of
immunophilins in the development of neuroprotectors has
emerged [9, 10].
Neuroimmunophilin ligands are a class of compounds
that can be used for the treatment of nerve injuries and
neurological diseases. These ligands can readily penetrate
the blood-brain barrier and are eﬀective in a variety of
animal models of ischemia, traumatic nerve injury, and
neurodegenerative disorders in human being [11].
Cyclosporin A and FK-506 have already been used
in humans (as immunosuppressant drugs). Both of them
exhibit neuroprotective actions, but only FK506 and its
derivatives have signiﬁcant neuroregenerative properties.
Tacrolimus is a macrolid antibiotic compound which
exhibits immunosuppressant eﬀects and interact with
the immunophilin FKBP12 (FK506-binding protein). The
resulting complex, in turn, can inhibit calcineurin, a
Ca2+ calcium/calmodulin-dependent serin/threonine phos-
phatase [12, 13].
Neuroprotective and neuroregenerative properties of
tacrolimus seem to act via diﬀerent mechanisms, because
FK506-relatedcompoundthatbindtoFKBP-12donotblock
calcineurin (as an immunosuppressant). Thus, FK506 has
the ability to enhance nerve regeneration and acts via a
calcineurin-independent mechanism [11, 14, 15].
Many studies assessed neuroprotective eﬀects of FK506,
but little is known about the neurotrophic eﬀectsof this drug
[11, 15, 16].
The time of injection may also play an important role
in the process of neurogenesis, so comprehensive research
regarding the eﬀects of diﬀerent times of injection seems
necessary [17].
In the present study, neurotrophic properties of FK506
in CA1 area of Wistar rat hippocampus were assessed
by histological outcome following ischemia/reperfusion in
diﬀerent periods of the drug injection.
2. Methods
In this study, we evaluate the eﬀects of repeated doses of
FK506 after ischemia at various times (IV injection exactly
at the time of reperfusion and repeated IP at 6-24-48-72
hours after reperfusion) on hippocampus CA1 pyramidal
cell numbers, diameters and number of apoptotic bodies by
using Nissl stain and TUNEL-labeled sections Figure 3.
All of the data was collected from the CA1 sector of
the hippocampus. The number of surviving pyramidal cells,
t h e i rd i a m e t e r sa n dn u m b e ro fd e a dc e l l sw e r ec o u n t e di n
control,shamandexperimentalgroupswhichreceivedsingle
and repeated doses of FK506 in various times of injection.
2.1. Animals. Adult male Wistar rats 12 to 13 weeks old and
weighing 250–300g from the Pharmacology Department
of Tehran University of Medical Sciences were used in
all experiments. The rats were housed under a 12-hour
light/dark cycle. They were allowed free access to food and
water.
All of them were housed in animal house for at least 5
days prior to experiments. All experiments were performed
attheDepartmentofAnatomy,SchoolofMedicineofTehran
University of Medical Sciences and Institute of Cognitive
Science Studies in 2010.
All procedures used in the study were approved by the
ethics committee for the use of experimental animals at
Institute for Cognitive Science Studies, Tehran, Iran.
2.2. Experimental Groups and Drugs. Animals were divided
randomly into 7 groups (n = 35) as described below.
(1) Control group: rats only anesthetized by pentobarbi-
tal sodium (40mg/kg).
(2) Sham group: After anesthesia by pentobarbital
sodium, common carotid arteries on both sides were
occluded for 20 minutes followed by reperfusion.
(3) Experimental Group 1: After anesthesia and ischemia
for 20min followed by reperfusion, 6mg/kg
Tacrolimus was injected intravenously (IV) at the
beginning of reperfusion phase.
(4) Experimental Group 2: After anesthesia and ischemia
for 20 minutes followed by reperfusion, 6mg/kg
Tacrolimus was injected (IV) at the beginning of
reperfusion phase. After 6 hours Tacrolimus was
injected intraperitoneally (IP) again with the same
dose.
(5) Experimental Group 3: After anesthesia and ischemia
for 20min followed by reperfusion, 6mg/kg Tac-
rolimuswasinjected(IV)atthebeginningofreperfu-
sion phase. After 24 hours, the injection was repeated
with the same dose intraperitoneally.
(6) Experimental Group 4: After anesthesia and ischemia
for 20min followed by reperfusion, 6mg/kg Tac-
rolimuswasinjected(IV)atthebeginningofreperfu-
sion phase. After 48 hour injection was repeated with
the same dose (IP).
(7) Experimental Group 5: After anesthesia and ischemia
in the same period, injecting a dose of 6mg/kg Tac-
rolimus (IV) at the beginning of the reperfusion
phasewasdone.After72hoursinjectionwasrepeated
with the same dose (IP).
Rats in groups ((1) to (7)) were sacriﬁced after 4 days,
and all brains were removed for histological assessment
(Nissl and TUNEL methods).
FK506 (solution, 5mg/mL ampule) was kindly gifted by
the Astellas Pharmaceutical Co (Osaka-Japan).
2.3. Surgical Procedures. To induce transient cerebral ische-
mia, rats were anesthetised with sodium pentobarbital an-
esthesia (40mg/kg, IP). A rectal temperature probe was
inserted, and body temperature was monitored and main-
tained at 37◦C using heating lamps. Both common carotid
arteries were exposed and freed from its carotid sheet, thenStroke Research and Treatment 3
the vagus nerves were carefully separated. Both common
carotid arteries were occluded for 20min using Yashargil
Aneurism microclips.
During ischemia, the animals were monitored for body
temperature, loss of righting reﬂex, and unresponsiveness to
gentle touch.
Subsequently, the carotid arteries were released and
inspected for immediate reperfusion. Recirculation of blood
ﬂow was established by releasing the clips and restoration
of blood ﬂow in the carotid arteries was conﬁrmed by
observation. Animals were returned to their home cage after
the surgery and kept separately for 4 days (96h). After this
period of time, rats were anesthetized intraperitoneally with
pentobarbital sodium (40mg/kg) and transcardiac perfusion
was performed with heparin (10U/mL) in 0.9% salin,
followed by 4% paraformaldehyde in 0.1M phosphate buﬀer
(PH = 7.4). Their brains were removed and postﬁxed in
the same ﬁxative for more than 3 days. Brains were rapidly
removed and put in the ﬁxator for more than 3 days.
2.4. Histopathologies. Paraﬃn-embedded coronal sections at
diﬀerent thicknesses were cut for diﬀerent staining methods,
3a n d1 0μm thickness for Nissl and Tunel staining respec-
tively, between 2.3 and 5mm posterior to bregma fortune.
2.5. Nissl Staining. For Nissl staining, 10μm-thick sections
were mounted directly onto gelatin-coated glass slides and
air-dried. The slides were stained with 1.0% cresyl violet,
dehydrated, and cover-slipped with Entellan. Eight photomi-
crographswerepreparedfromeachanimal(betweenthelevel
of 2.3 and 5mm posterior to bregma fortune according to
the paxinos atlas). Three of them were selected and counted
at ×400 magniﬁcation of light microscope by a blinded
investigator.Onlycellswithanevidentnucleusandnucleolus
were included. Images were taken at ×400 magniﬁcation
with a microscope (Olympus AX-70) and analyzed by using
image tool 2 software.
2.6. TUNEL Staining. For TUNEL staining, paraﬃn blocks
were cut into 3μm thickness coronal sections. To detect
apoptotic cells, TUNEL staining was performed using an
In Situ Cell Death Detection Kit (Roche, Mannheim, Ger-
many) according to the manufacturer’s protocol. Brieﬂy,
the sections were deparaﬃnized in xylol, rehydrated by
successive series of alcohol, washed in phosphate-buﬀered
saline (PBS), and deproteinized (or permeabilized) by
proteinase K (20μg/mL) for 30min at room temperature.
Then, the sections were rinsed and incubated with 3% H2O2
in methanol for 10min in the dark to block endogenous
peroxidase (POD) then the sections were incubated in the
TUNEL reaction mixture for 60min at 37◦C in humidiﬁed
atmosphere and rinsed with PBS. Then, sections were
visualized by using converter-POD for 30min in 37◦Ca t
humidiﬁed atmosphere in the dark then rinsed with PBS and
50–100μL DAB substrate [diaminobenzidine (DAB)] was
added and rinsed with PBS then all slides were mounted by
cover slip and analysis by light microscope. Coronal sections
of the CA1 area of hippocampus at the level of 2.3 and
5mm posterior to bregma according to the paxinos atlas
(four sections per animal) [18] were examined and TUNEL-
positive cells were quantiﬁed using light microscopy at ×400
magniﬁcation. Values (per mm2)f r o mf o u rs e c t i o n sw e r e
averaged to calculate the number of TUNEL-positive cells.
All counting procedures were performed blindly.
2.7. Statistical Analysis. T h ed a t aw e r ee x p r e s s e da sm e a n±
standard error of measurement (S.E.M.). Statistical analysis
of the data for multiple comparisons were performed by
one-way ANOVA (SPSS 13 software program) followed by
Tukey’s test. Statistical signiﬁcance was deﬁned as a P value
≤ 0.05.
3. Results
After 20 minutes of bilateral Common Carotid Arteries
(CCA) occlusion, marked CA1 cell loss was noticed in all
subject groups (Figure 1). We found a statistically signiﬁcant
diﬀerence in CA1 cell loss among controls and all other
subjects groups except group 6 (P = 0.233). Although
marked decrease in CA1 hippocampal region cell diameters
was observed after 20 minutes of bilateral CCA occlusion in
all groups, diﬀerences were statistically signiﬁcant only for
group 2 versus controls (P = 0.03).
Figure 2 shows the relationship of repeated injections of
FK506 on ischemia reperfusion-induced CA1 cell death in
various times on cell diameter.
We next carried out TUNEL staining which detects DNA
damage characteristic of apoptosis after bilateral common
carotid occlusion for 20 minutes.
The number of TUNEL-positive cells was signiﬁcantly
increased compared with control group in the CA1 region
of the hippocampus after ischemia. There was a signiﬁcant
diﬀerence between control group versus groups 2 (P =
0.001) and 3 (P = 0.023), which means that apoptotic cells
were signiﬁcantly decreased by repeated injection of FK506
in this region.
Figure 4 shows the relationship of FK506 treatment on
number of apoptotic cell bodies in CA1 region in all groups
with various times of injection.
Our results show that neurodegenerative changes were
notmitigatedbyasingleFK506applicationandthatrepeated
applications of tacrolimus ameliorate not only CA1 damage
and neurodegeneration, but also have protective eﬀects,
which can reduce CA1 cell death.
4. Discussion
Our study demonstrates that rats which are subjected to 20-
min brain ischemia showed loss of the pyramidal cell in
numberfollowedbyDelayedNeuronalDeath(DND)inCA1
region of hippocampus. Our data extends previous ﬁndings
oftheCCOmodelsofanimalswhichshowedtransientglobal
cerebral ischemia/reperfusion causing neuronal cell death
[19, 20].4 Stroke Research and Treatment
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Figure 1: Photomicrographs of coronal sections (cresyl violet stain) of the hippocampus. (a) Control group. (b) Rats subjected to ischemia
operation. (c) Ischemia plus single dose of FK506 (IV injection exact the time of reperfusion. (d) Ischemia plus repeated doses of FK506 (IV
injection exact the time of reperfusion and IP injection at 48h after reperfusion). Scale bar = 30μm.
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Figure 2: The relationship of repeated injections of FK506 on
ischemia reperfusion in various time on pyramidal cell number of
CA1. ∗P<0.05 versus control and repeated dose/reperfusion time,
48h later groups.
In the ﬁrst experiment, (group 3) a single intravenous
injection of FK506 (6mg/kg) exactly at the time of reper-
fusion, did not signiﬁcantly increase the number and size
of pyramidal cells of the CA1 region of the hippocampus;
however, when the repeated dose of this drug was used
after 48h with the same concentration, signiﬁcant increase
was observed in the number and size of these cells. our
data supported the previous study which demonstrated
that repeated FK506, application in contrast to a single
injection regime reduces ischemia induced CA1 pyramidal
cell [17]. We also found out that the single dose could not
decrease the number of Tunel-positive cells in the ischemic
region but repeated dose of this drug can decrease the
number of Tunel-positive cells in the ischemic region. The
potentimmunosuppressantwasshowntobeneuroprotective
conﬁrming previous studies [21–23].
There are studies reporting that FK506 can speed up
nerve regeneration after peripheral nerve injury in rats [24].
In addition, it increases axonal regeneration following spinal
cordinjuryinadose-dependentfashion[25].AppliedFK506
enhances the sprouting of axonized central intrinsic neurons
such as retinal ganglion cells after optic nerve crush [26].
FK506, and its derivative L-685,818 treatment of rats with
crushed sciatic nerves, enhances both functional recovery
and regenerated myelinized ﬁbers [27]. FK506 can exertStroke Research and Treatment 5
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Figure 3:TheeﬀectofFK506(6mg/kginjectionIVand4injections
IP in various times) on pyramidal CA1 cells diameters after
transient global ischemia. a,b,cP < 0.05 control (a) versus sham-
operated (b) and repeated dose/reperfusion time +72h later (c)
groups.
0
1
2
3
4
5
6
7
8
9
10
Groups
N
o
.
o
f
a
p
o
p
t
o
t
i
c
b
o
d
i
e
s
Control
Sham operated
Single dose at reperfusion time
Repeated dose/reperfusion
time + 6h later
Repeated dose/reperfusion
time + 24h later
Repeated dose/reperfusion
time + 48h later
Repeated dose/reperfusion
time + 72h later
a, c
a, b
a, d
a, b, c, d
Long term
Figure 4 :B a rg r a p hs h o w st h ee ﬀect of repeated doses of FK506
on ischemia-induced, hippocampal pyramidal CA1 cell death
(apoptotic body) in various times of injection. a,b,cP < 0.05 control
versus sham, single dose and long term groups.
neurotrophic eﬀects on the penile innervations that promote
erectile function recovery in rats after extensive CNS injury
[28]. Our ﬁndings also show that FK506 can improve the
number and size of pyramidal neurons in the hippocampal
CA1 region after global transient brain ischemia in a time-
dependent fashion of repeated injection.
Tissueinjuryduetoischemiaistheresultofapathophys-
iologicalcascadewhichcanincreaseglutamateconcentration
and stimulate NMDA and other glutamate receptors which
can increase Ca2+ e n t r ya n dc a u s ec e l ld e a t h[ 29].
DND in the hippocampus following global ischemia
w a sﬁ r s tr e c o g n i z e d[ 30]. Feature of DNA ladders on gel
electrophoresis of extracted nuclear DNA is a key feature in
apoptotic cells which have been identiﬁed after ischemia of
12 or 20 minutes in the rat and 5 or 20 minutes in the gerbils
[31, 32].
Several studies were done in order to ﬁnd the mechanism
of ischemic cell death, but up to now, the deﬁnite mecha-
nism underlying DND followed by ischemia is not found.
Calcineurin is one of the most important enzymes which is
necessary to regulate the phosphorilation activity of many
proteinsinneurons[33,34].Braincalcineurinconcentration
is 3–10 times higher than other tissues [35].
FK506, which is one of the immunosuppressive drugs,
bindstotheimmunophilinFKBP12(FK506bindingprotein)
and creates a new complex. This FKBP12-FK506 complex
interacts with and inhibits calcineurin [36]. Calcineurin
is a common target of FKBP-FK506 complexes [37]. This
drug crosses the blood-brain barrier and has neuroprotective
eﬀect [38–40]. In this study, it seems that the same mecha-
nism causes this protective eﬀect on the pyramidal neurons
of CA1 region.
Several studies have reported that FK506 acts as a neuro-
protectiveagentinseveralmodelsoffocalandglobalcerebral
ischemia in rats, gerbils, and primates, and it can inhibit NO
production which contributes to the neuroprotective eﬀect
of this drug on DND in the hippocampus [41–46].
Our results are not only in accordance with previous
studies, but also shows that FK506 as a neuroprotective agent
can ameliorate DND.
Our ﬁndings also conﬁrm with the previous ﬁnding
which reported that a single IV injection of FK506 provided
no protection, but this result does not correlate with the
study which reported that a single-dose injected (3 or
10mg/kg) IV has neuroprotective eﬀect on pyramidal cells
of robust when injected immediately after ischemia [47,
48].
Several studies reported that neurogenesis had occurred
after ischemia in the CA1 region [49]. Subgranular and
subventricularzonesaretwositeswhichareneurogenic areas
in intact adult mammalian brain and produce newborn
neurons [50]. In normal conditions, there is no neurogenic
region, but in animal models of stroke, newborn neurons
from the subependymal zone might be induced [51]. The
new cells which are generated in subgranular zone of
hippocampus diﬀerentiate into granular neurons which
eﬃciently develop and change to mature neuronal cells [52–
54].6 Stroke Research and Treatment
Asmentionedbefore,therewasnostatisticallysigniﬁcant
diﬀerence in number of pyramidal cells between the rats
that were given repeated doses of tacrolimus after 48 hours
andthecontrolgroup. Accordingtopreviousstudies, further
investigations are needed for determining whether these cells
are induced by brain endogenous factors or not.
5. Conclusion
It was concluded that 20-min brain ischemia showed loss of
the pyramidal cells in number and size followed by DND in
the hippocampal CA1 region. Repeated dose of FK506 via
diﬀerent mechanisms of action can increase the number and
the size of pyramidal cells of the CA1 region of hippocampus
and has a neuroprotective eﬀect against DND.
It seems that when FK506 was given repeatedly as a com-
bination of IV (at the beginning of reperfusion phase) plus
IP injection (48h after reperfusion), it may have stimulated
the endogenous zones of the brain, and a neurotrophic eﬀect
was provided. Such an eﬀect may depend on a repeated dose
protocol.
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